Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NPC).

Trial Profile

Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NPC).

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2009

At a glance

  • Drugs Gemcitabine; Oxaliplatin
  • Indications Nasopharyngeal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 18 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2008 The expected completion date for this trial is 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 18 Jun 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top